Eli Lilly and Company plans to invest $3 billion in China over the next decade. This capital will expand the company's supply chain and establish production capacity for orforglipron.
Orforglipron is an experimental, once-daily oral GLP-1 medication designed for weight loss. Lilly submitted a marketing application for the drug to Chinese regulators in late 2025.
The investment focuses on creating a localized manufacturing and supply system for oral medications within China. This strategy positions the company to compete in China's expanding obesity treatment market, pending regulatory approval.